Hanza har slutfört förvärvet av Milectria, en finsk kontraktstillverkare med hög exponering mot förs...
Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first pa...
Redeye updates its estimates and fair value range following Enviro’s rights issue, where we have als...
Redeye is encouraged by today’s news of Nekkar’s subsidiary Intellilift and its JV, InteliWell, anno...
Redeye is positive about the results from CLS’s study at Skåne University Hospital.
Redeye provides its initial comments on Xspray following last night’s press release confirming a Com...
Redeye takes a positive stance towards Addnode’s acquisition of SolidCAD.
* Q3 sales -36% vs cons, EBIT SEK -3m vs cons 91m * Main reason is delayed deliveries, Q3 order inta...
Redeye comments on Invisio’s preliminary announcement of Q3-results which were lower than expected o...
Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivota...
Redeye shares its view on Sleep Cycle ahead of the Q3 report due on 24 October.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q3 2025 amounte...
Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its comple...
Redeye comments on Physitrack ahead of its Q3 results, due on 21 October (rescheduled from 31 Octobe...
Redeye updates its estimates and valuation after Mendus’ clinical strategy update.
